Gastroenterology

Each capsule provides :

Lactobacillus Reuteri DSM 17648 (Pylopass ) – 100 mg

CUREXIL

A Novel approach

A Novel approach that eradicates H. pylori; Manages Gastritis & Peptic ulcer

Emerging evidences suggest an inhibitory effect of Lactobacillus (CUREXIL) on H. pylori.

MODE OF ACTION

CUREXIL forms coaggregates with H. pylori to decrease the overal load in the stomach thereby decreasing the risk of developing gastric & peptic ulcer disease.

INDICATIONS

• To control & eradicate H. Pylori infections with or without antibiotics
• Prevention & management of Peptic ulcer
• Reduction of Gastritis symptoms and promotion of natural healing.

BENEFITS

• Supports digestive health by ensuring normal gastric acidity, gastric mucosal protection & reducing the colonization of H. pylori in the stomach.
• Supplementation with CUREXIL can improve the quality of life, promotes the gastric wellbeing & balancing the healthy microbiot.